The company, located in Guangzhou’s Nansha District, has invested 180 million Yuan for a protein proeduction facility which can handle 15.000 t/year. The company features the production of proteins from urine, e. g., Kailikang, a human protease which dilates arteries and inhibits platelet aggregation.
China Bio news release, June 25, 2015